Obesity is associated with significantly increased risk for diarrhoea after controlling for demographic, dietary and medical factors: a cross-sectional analysis of the 2009-2010 National Health and Nutrition Examination Survey.


Journal

Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234

Informations de publication

Date de publication:
11 2019
Historique:
received: 09 07 2019
revised: 14 08 2019
accepted: 22 08 2019
pubmed: 19 9 2019
medline: 26 5 2020
entrez: 19 9 2019
Statut: ppublish

Résumé

Obesity is associated with increased risk for various gastrointestinal and liver diseases. However, the relationship between obesity and abnormal bowel habits is poorly understood. To investigate the relationship between body mass index (BMI) and bowel habit, controlling for clinical, demographic and dietary factors, in a representative sample of the United States adult population METHODS: Data were extracted from the 2009-2010 National Health and Nutrition Examination Survey. Survey responses were included in this study if respondents completed the bowel health questionnaire (BHQ), were ≥20 years of age, and did not report history of IBD, celiac disease or colon cancer. BMI was divided into the following categories: underweight, normal weight, overweight, obese and severely obese. Stepwise logistic regression provided risk ratios of constipation and diarrhoea controlling for confounding factors (dietary, life-style, psychological and medical). A total of 5126 respondents completed the BHQ, had BMI data available, and met eligibility criteria. Of these, 70 (1.40%) were underweight, 1350 (26.34%) were normal weight, 1731 (33.77%) were overweight, 1097 (21.40%) were obese and 878 (17.13%) were severely obese. Up to 8.5% of obese and 11.5% of severely obese individuals had chronic diarrhoea, compared to 4.5% of normal weight individuals. Stepwise regression revealed that severe obesity was independently associated with increased risk of diarrhoea. Obesity is positively associated with chronic diarrhoea in a nationally representative US adult population after adjusting for several known confounding factors.

Sections du résumé

BACKGROUND
Obesity is associated with increased risk for various gastrointestinal and liver diseases. However, the relationship between obesity and abnormal bowel habits is poorly understood.
AIM
To investigate the relationship between body mass index (BMI) and bowel habit, controlling for clinical, demographic and dietary factors, in a representative sample of the United States adult population METHODS: Data were extracted from the 2009-2010 National Health and Nutrition Examination Survey. Survey responses were included in this study if respondents completed the bowel health questionnaire (BHQ), were ≥20 years of age, and did not report history of IBD, celiac disease or colon cancer. BMI was divided into the following categories: underweight, normal weight, overweight, obese and severely obese. Stepwise logistic regression provided risk ratios of constipation and diarrhoea controlling for confounding factors (dietary, life-style, psychological and medical).
RESULTS
A total of 5126 respondents completed the BHQ, had BMI data available, and met eligibility criteria. Of these, 70 (1.40%) were underweight, 1350 (26.34%) were normal weight, 1731 (33.77%) were overweight, 1097 (21.40%) were obese and 878 (17.13%) were severely obese. Up to 8.5% of obese and 11.5% of severely obese individuals had chronic diarrhoea, compared to 4.5% of normal weight individuals. Stepwise regression revealed that severe obesity was independently associated with increased risk of diarrhoea.
CONCLUSION
Obesity is positively associated with chronic diarrhoea in a nationally representative US adult population after adjusting for several known confounding factors.

Identifiants

pubmed: 31532005
doi: 10.1111/apt.15500
pmc: PMC6800600
mid: NIHMS1047951
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1019-1024

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK007760
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Références

Am J Gastroenterol. 2019 Jan;114(1):135-142
pubmed: 30410038
Gastroenterology. 2017 May;152(7):1656-1670
pubmed: 28192107
Gastroenterology. 2011 Nov;141(5):1792-801
pubmed: 21820992
Am J Gastroenterol. 2004 Sep;99(9):1801-6
pubmed: 15330922
Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G382-8
pubmed: 18617555
Arch Intern Med. 2001 Sep 10;161(16):1989-96
pubmed: 11525701
Am J Gastroenterol. 2010 Apr;105(4):731-5
pubmed: 20372121
Am J Gastroenterol. 2004 Apr;99(4):711-8
pubmed: 15089906
Biochimie. 2016 May;124:11-20
pubmed: 26133659
Clin Gastroenterol Hepatol. 2019 Apr 4;:
pubmed: 30954714
Gut. 2005 Oct;54(10):1377-83
pubmed: 15917313
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
Scand J Gastroenterol. 1997 Sep;32(9):920-4
pubmed: 9299672
Am J Gastroenterol. 2018 Apr;113(4):593-600
pubmed: 29610515
Am J Clin Nutr. 2004 Apr;79(4):537-43
pubmed: 15051594
Int J Endocrinol. 2018 Mar 22;2018:4095789
pubmed: 29849617
PLoS One. 2012;7(5):e37160
pubmed: 22629362
Am J Gastroenterol. 2004 Sep;99(9):1807-14
pubmed: 15330923
Neurogastroenterol Motil. 2004 Aug;16(4):413-9
pubmed: 15305996
Am J Gastroenterol. 2013 May;108(5):796-803
pubmed: 23567352
Circulation. 2006 Feb 14;113(6):898-918
pubmed: 16380542
Aliment Pharmacol Ther. 2013 Oct;38(8):967-76
pubmed: 23981126

Auteurs

Sarah Ballou (S)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Prashant Singh (P)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Vikram Rangan (V)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Johanna Iturrino (J)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Judy Nee (J)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Anthony Lembo (A)

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH